Turtles in the BVI, female Viagra and new partners

A Hawksbill sea turtle in the BVI

The Photo: A Hawksbill sea turtle on the bottom of a bay in the BVIs. See how well its coloration blends with the bottom flora and fauna. 

Sea turtles in the BVIs: The British Virgin Islands has a Sea Turtle Hunting season December 1st through March 31st. Hunters are legally allowed to harvest Hawksbill and Green Sea Turtles, both endangered animals. Hawksbill turtles (must be 15+inches carapace length) and Green turtles (24 +inches carapace length) but these sizes still put them in the late juvenile / sub-adult age. There is a moratorium on loggerhead turtles, leatherback turtles, & all sea turtle eggs.

Sea turtles are breeding now and interfering with their egg laying is prohibited. Fortunately for us most of their breeding grounds and egg laying beaches are on the northern side of Tortola. So far we have only had only one female, a huge leatherback, come ashore to nest and she is on one end of the beach up against the cliff out of the way where it is sunny during the day. Marvin and I were on the beach after midnight where he was doing his biologic best to breed me when we heard her digging her nest.  We were almost finished so he came (he had already given me my pleasure) and we went to watch her finish digging, lay her eggs and cover them with several feet of sand then reenter the water. She will probably be back with another batch in a few weeks.

There is an active movement to ban the hunting of all varieties and sizes of sea turtles in the BVIs, but they constitute an important boost to the economy during hunting season and they are delicious to eat.     

Flibanserin a female Viagra?: In early June an advisory panel to the USFDA recommended approval of Flibanserin, a drug touted by Sprout Pharmaceuticals to treat Hypoactive Sexual Desire Disorder (HSDD) in women--a persistent lack of desire for sex. The advisory panel’s 18-6 vote came with stipulations from those in favor that measures be taken to reduce the drug's side effects that can include low blood pressure, fainting, sleepiness and nausea.

HSDD was recognized as a distinct sexual function disorder for more than 30 years, but was removed from the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders in 2013, and replaced with a new diagnosis called female sexual interest/arousal disorder (FSIAD).

In trials for women taking Flibanserin the average number of times they had “satisfying sexual events” rose from 2.8 to 4.5 times a month. The majority of adverse events being mild to moderate and were resolved during the treatment. The most commonly reported adverse events included dizziness, nausea, fatigue, somnolence and insomnia. That’s almost a doubling of satisfying events so for women suffering from FSIAD the side effects may be worth putting up with them. Thank God I’m not one of them!

How Flibanserin works: [from: http://en.wikipedia.org/wiki/Flibanserin] “The proposed mechanism of action refers to the Kinsey dual control model. Several sex steroids, neurotransmitters, and hormones have important excitatory or inhibitory effects on the sexual response. Among the neurotransmitters, the excitatory activity is driven by dopamine and norepinephrine, while the inhibitory activity is driven by serotonin. The balance between these systems is relevant for a healthy sexual response. By modulating these neurotransmitters in selective brain areas, Flibanserin, a 5-HT1A receptor agonist and 5-HT2A receptor antagonist, is likely to restore the balance between these neurotransmitter systems. 5-HT1A receptor activation likely plays a significant role in the empathogenic effects of serotonin releasing agents (SRAs) like MDMA ("Ecstasy") as well.”

“Flibanserin is a 5-HT1A receptor agonist and 5-HT2A receptor antagonist that had initially been investigated as an antidepressant. Preclinical evidence suggested that Flibanserin targets these receptors preferentially in selective brain areas and helps to restore a balance between these inhibitory and excitatory effects.”

HPV inoculations and biocides: Fortunately all the new girls have had their Gardasil shots and because of the high number of male partners we are all sharing we are using a new biocide from Labia Labs, a major improvement to DiveGel+ called DiveGel++. The new formulation of silicone lube can be safely used with silicone cervical barriers for dive-sex and is easier to remove from lingerie and swimsuits, but of course a silicone lube isn’t conducive to cunilingus unless the lube is applied afterward. The lube also has an improved vaginal pH balance and the biocide is more effective with no side effects.  

The new men’s sexual education continues: In my post for May 31, 2015 I mentioned five couples who had come down for the women (who are friends or Taryn’s at Cambridge) to get a bit of sun and a few hours of familiarization training as ‘Hostesses’ at a fetish club this summer since they want to experience the fetish community first hand as background for their study of medicine and eventually psychiatry. The men in my circle as well as the boyfriends they brought with them are keeping the new girls filled with fresh semen. But it is the five new STI screened men that my circle and I were particularly pleased to have joined us. While they have great sexual stamina they aren’t all that worldly though several of them think they are the world’s gift to women.

For me there is nothing more erotic that taking a new unprotected man inside me for the first time and the few after that are marvelous as well as I learn his lovemaking technique, especially if he is well endowed. As this is written I’m CD10 and fertile and should ovulate on Friday the 12^th so I need to be sure I’m protected with a cervical barrier of some sort as I enjoy the new scent, the color of their eyes and hair, the feel of them grasping my hips or shoulders to hold me in position while they work on my G-spot or thrust into my anterior fornix squeezing his glans when I have a Reflexions flat spring diaphragm inserted and his thrusting rubs the anterior rim against my G-spot. For most encounters I can delay my most intense orgasms to have the contractions occur when he is ready and we tip over the edge into toe curling, gasping, screaming ecstasy together.

Bea has set all the new men back on their heels. When an 18 y/o who appears to be an ingénue milks a man’s penis when he takes her to bed for the first time thinking he is going to show her what sex with a man is all about it can be a shock to his masculinity.  On their first encounter she always mind-fucks him, giving him pompoir and it’s usually the first time for him! She can quickly have a man on a psychological penis leash if he isn’t careful as they can easily become addicted to her amazing muscular encounters and become in thrall to her grip. Fortunately she hasn’t had her head turned by the effect she has on men, at least not yet.

Service school: The five Cambridge grad students who have come to me for ‘hostess familiarization training’ as Taryn called it are all popping 500mg fast acting capsules of acetaminophen because of what one called pelvic trauma. I had cautioned them to try to avoid bruising of the mons pubis from a partner’s too forceful thrusting when his pelvis slams into hers, but for some it takes personal experience to drive the lesson home, in a manner of speaking.

The trainees were told to bring three pairs of 5” pumps (stripper heels) as well as at least one pair of good quality leather ballet-boots which they were fitted for at the Blackthorn fetishwear shop. The boots are custom made by a cobbler in London. They are well made of good leather, provide plenty of ankle support and the heels won’t break or come off easily nor will the reinforced toe-boxes collapse. The boots aren’t up to Gepetto’s standards, but they only cost £350 rather than the £2,000 that his would cost. I am very pleased how well their ballet-boots fit and they come with a quarter of a stress ball in the toe-boxes. It only took two sessions to teach them that the boots have to be laced extremely tight to grip the instep. Correctly laced 90% of the wearer’s weight is supported by the instep being wedged between the tongue and laces and the shank of the boot while the remaining 10% is on her toes pressed into the stress ball. They are actually doing very well wearing them, becoming accustomed to walking confidently in them and the thick leather of the shafts provide good ankle support. They can keep up during our regular 30 minute ballet-boot exercise session where my wards and I walk around the house wearing heel guards to protect the floors and carpets and up and down stairs to keep our feet and legs used to the needs of ballet-boot wearing.

I would have liked the girls to also train in pointe-shoes as that is a skill that few hostesses have and would increase their desirability, but while they had all taken ballet and a year or two of pointe they do not have the muscles nor stamina for hostessing en pointe and there is no time to build up the needed strength and flexibility in their legs, feet and ankles. We started with the easiest shoes first being penetrated from behind while in stripper heels while bent over with the hands griping the knees. This also gave the students some relief from being penetrated from the front where their bruised pubic bones would almost certainly be hit. And now we have progressed to being entered from the rear while standing in ballet-boots either bent over holding on to a barre, chair back or counter top, or just bent over holding on to her knees, but that takes much better balance than when entered that way in stripper heels. 

Barrier training and identity theft

All-Flex diaphragm compressed for insertion

The All-Flex as a training barrier: The 12-14 y/os at St Lucy’s in our Feminine Hygiene class are fitted with an All-Flex as their first training barrier because it is the easiest style to insert correctly. Every girl is fitted regardless of any other method of contraception she is using. For anyone reading this who says that 12 y/os are too young to be using birth control, I say, “Get Real!” It’s true that the age of consent in Nevada is 16, but we teach the use of a diaphragm as a method of flow control during a woman’s period. It just so happens that it can also be used as a contraceptive device and for URTP (upper reproductive tract protection) when she is old enough to have dive-sex. Most of the girls past menarche are on some form of hormonal or IUD method of birth control anyway because their parents have approved it. The usual reason given is ‘to regulate their cycles’ even when everyone is aware the teens are using it for protection while actively participating in horizontal sports.

Elke and Flibanserin – an update: Boehringer Drops Female Desire Drug. Germany's Boehringer Ingelheim said today (10-08-2010) it will discontinue development of its investigational compound Flibanserin for the treatment of Hypoactive Sexual Desire Disorder because of FDA requests for further support the efficacy and safety profile of the drug. “The decision was not made lightly, considering the advanced stage of development,” said a Boehringer executive. “We remain convinced of the positive benefit-risk ratio of Flibanserin for women suffering with HSDD”. Returning readers will remember that in my entries for June 17 and July 8, 2010 I wrote about Elke, Adolph’s pool assistant and German arm-candy, being on Flibanserin. Perhaps it had some placebo effect for a while but she is off it now as the improvement she seemed to have disappeared.

Fall pregnancies: Last week at the clinic we began to see the usual crop of Fall pregnancies. There was only one St Lucy’s girl. The other seven came from UNLV (3), local public high schools (3) and the last one a new showgirl at a rival casino who came from a casino in Atlantic City. This phenomenon occurs each Fall as young women switch from their Summer vacation or intern jobs to Fall back-to-school routines. All were within the 8 week maximum for taking Mifeprex but five of the six (the seventh miscarried) had menstrual extractions. The sixth, the showgirl, took Mifeprex.

Boned at the Barre: The St Lucy’s girl is a transfer student from Los Angeles who is taking ballet and was using Lybrel the estrogen/progestin pill (90 mcg levonorgestrel and 20 mcg of ethinyl estradiol) that is taken every day for 365 days. That dosing regimen is supposed to stop your periods, but break-through bleeding is common for 30% of users for up to 6 months while user’s bodies get used to the hormone levels. In June of this year the maker, Wyeth/Pfizer, repackaged Lybrel in a new blister package and the St Lucy’s girl had a hard time remembering to take her pill from a blister pack rather than the old ClickCase. She liked the ClickCase and thinks the blister pack is common. The psychology of that probably led to her not taking her pills correctly and eventually her pregnancy. Counting back it appears she had been inseminated when she arrived on campus. She tested negative for hCG during her mandatory pelvic exam the day she arrived and hadn’t had sexual contact with a partner for the next six weeks which means she conceived a day or two after she arrived.

Since she never had a period she didn’t have any warning that she was preggers until her breasts began to swell and the milk glands surrounding her nipples became prominent as they increased in size. Three weeks later during one of her first times being penetrated from the rear while en pointe, in the usual Boned-at-the-Barre position - feet a la seconde penetrated from the rear while bent over holding on to the barre - she had her cervix rammed several times by her partner and began to hemorrhage. She fainted and miscarried right in the studio bleeding all over a new pair of Gaynors she had just bought to have sex with her fave ballet teacher. She was rushed to the clinic and had a menstrual extraction to make sure that all the fetal tissue and placenta were expelled. She was put on a ten day regimen of antibiotics and told not to have any sexual activity that would cause her uterus to cramp for the next week while her endometrium was replaced.

Identity theft: I’ve mentioned in earlier entries that my women escort candidates and St Lucy’s students who are fitted for gas guards have RFID chips put in them so we can tell who is absent from class and ensure that they are wearing their gas guards before they enter the water for dive-sex labs where partners will finish inside each student during her dive. The RFID chips also help identify women when they are wearing DiveRubber or encasement suits where faces and identifying body markings (tats, scars, blemishes, etc) are hidden so from a distance it is almost impossible to know who is wearing the rubber suit. We have had instances where someone tried to have another woman take an exam dressed in the absent students DiveRubber or fetish gear. We are seeing gym-bag, dance-bag and reg-bag thefts in women’s locker rooms apparently to get their gas guards with RFID chips in them so they can pretend to be the student/dancer when dressed in fetishwear or dive gear. Wearing another woman’s diaphragm with her RFID chip it makes it much easier to get into some of the women’s secure areas at St Lucy’s and in the escort training areas at the casino. To combat that we have gone to biometric scanning of thumbprints as a cross-check to get into women’s secure areas.

Big Pharma and female desire

Flibanserin – Female Viagra?

The New York Times
June 16, 2010
By DUFF WILSON

Push to Market Pill Stirs Debate on Sexual Desire

Ever since Viagra met blockbuster success in 1998, the drug industry has sought a similar pill for women.

Now, a German drug giant says it has stumbled upon such a pill and is trying to persuade the Food and Drug Administration that its drug can help restore a depressed female sex drive. The effort has set off a debate over what constitutes a normal range of sexual desire among women, with critics saying the company is trying to turn a low libido into a medical pathology.

On Wednesday, an F.D.A. staff report recommended against approving the drug, saying the maker, Boehringer Ingelheim, had not made its case and that the benefits of the daily pill did not outweigh its side effects, which included dizziness, nausea and fatigue.

That staff report came ahead of a meeting Friday by an F.D.A. advisory panel of experts who are to vote on whether to recommend that the agency approve the pill, which would be the first drug aimed specifically at a low sex drive in premenopausal women.

F.D.A. staff reports carry weight but do not always sway how advisory panels vote, and advisory votes do not always predict what the F.D.A. might finally decide.

Some analysts forecast that if the drug does reach the market, it could have annual sales in this country of $2 billion — or about equal to the current combined annual American sales of the men’s drugs Viagra, Levitra and Cialis.

In the last month, Boehringer has been trying to lay the consumer groundwork with a promotional campaign about women’s low libido, including a Web site, a Twitter feed, a Discovery Channel documentary and a publicity tour by Lisa Rinna, a soap opera star and former Playboy model, who describes herself as someone who has suffered from a disorder that Boehringer refers to as a form of “female sexual dysfunction.”

There is no dispute that some women have a depressed level of sexual desire that causes them anguish. Boehringer cites a condition — hypoactive sexual desire disorder — that is included in the Diagnostic and Statistical Manual of Mental Disorders, a reference book for psychiatrists and insurers.

But many experts say that unlike sexual dysfunction in men — which has an obvious physical component — sexual problems in women are much harder to diagnose. And among doctors and researchers, there is serious medical debate over whether female sexual problems are treatable with drugs. Some doctors advocate psychotherapy or counseling, while others have prescribed hormonal drugs approved for other uses.

There is also debate over how widespread hypoactive sexual desire disorder actually is among women. The medical literature, including articles in the prestigious New England Journal of Medicine, indicate numbers above 10 percent, but such studies have been financed by drug companies.

Critics say Boehringer’s market campaign exaggerates the prevalence of the condition and could create anxiety among women, making them think they have a condition that requires medical treatment.

“This is really a classic case of disease branding,” said Dr. Adriane Fugh-Berman, an associate professor at Georgetown University’s medical school who researches drug marketing and has studied the campaign. “The messages are aimed at medicalizing normal conditions, and also preying on the insecurity of both the clinician and the patient.”

Boehringer developed the drug, Flibanserin, as an antidepressant, but it failed to lift depression. The company says it learned serendipitously that the pill, taken daily for weeks, could restore female libido.

Dr. Peter J. Piliero, Boehringer’s director of medical affairs in the United States, says the lack of libido to the point of distress is a serious problem for some women.

“This is a real disease,” Dr. Piliero said in an interview. “There’s an unmet medical need among premenopausal women to have a treatment.”

Boehringer says the drug reduces the brain chemical serotonin, which can blunt sexual desire, and increases dopamine and norepinephrine, which improve desire, the company said. By acting on a woman’s brain, it takes a different approach from hormonal drugs or the action of Viagra for men, which increases blood flow.

Boehringer’s application for F.D.A. approval said that its two key 24-month studies, of 1,323 premenopausal women who said they suffered distress over lack of libido, had found small but statistically significant improvements. The women lived in the United States or Canada, were mostly married, well-educated and found to have the sexual desire disorder but were otherwise healthy.

In results reported last fall at a medical conference in Europe, the drug was found to increase self-reported “sexually satisfying events” to 4.5 a month on average. The reported events, which did not have to include orgasm, compared with 3.7 a month by women taking a placebo and 2.7 by those who did not take any pills.

The F.D.A. staff report on Wednesday, though, said that Boehringer’s data had not sufficiently demonstrated a second criterion the agency had set for approving such a drug — specifically, that women also report an increased level of sexual desire. The F.D.A. required daily self-reporting by the women in the studies; Boehringer said it had provided monthly reports.

Lara Crissey, a spokeswoman for Boehringer, declined to comment on the F.D.A. staff report.

Other drug companies that have sought a drug to elevate women’s sexual desire have included Pfizer, which spent several years trying to show that its drug Viagra could work for women as well as men. When Pfizer ended that research in 2004, it said in a news release that female sexual disorders resulted “from a broad range of medical and psychological conditions.”

Procter & Gamble sought F.D.A. approval for a skin patch to raise the testosterone levels of women who had had their uterus and ovaries removed, but it was rejected in 2004 because of possible links to breast cancer and cardiovascular disease. In 2006, though, European regulators, saying the testosterone patch appeared safe at low doses, approved that drug to treat depressed sexual desire in women whose uterus and ovaries had been surgically removed.

BioSante Pharmaceuticals, a company in Illinois, is in late-stage testing of another testosterone patch product which it hopes to submit to the F.D.A. next year. And Vivus, a drug development company, is testing a testosterone-based daily abdominal spray for women which it says has proved effective in early trials. And other research is focusing on the antidepressant buproprion, better known as Wellbutrin or Zyban.

Dr. Steven E. Nissen, a Cleveland Clinic cardiologist and a member of the 2004 F.D.A. panel that unanimously rejected the testosterone patch, said that the depressed desire disorder was a real medical condition, especially for middle-age or older women, with both physiological and psychological causes.

“I got a lot of hate mail after that vote,” Dr. Nissen recalled. “People wrote me and said, ‘You men have your Viagra, why are you denying us this?’ I said hey, I’m just trying to do the right thing. It needs to be scientifically sound.”

Dr. Nissen said he had not studied the Boehringer drug.

Leonore Tiefer, a psychologist and professor at New York University who has researched the topic of female sexual desire for more than a decade and plans to testify to the F.D.A. panel on Friday, said Boehringer had gone too far with its publicity effort.

“Women’s sex lives are often a struggle, a disappointment, an archipelago of regret,” she said. “Is there a small group of women who could benefit from medical intervention — probably.”

But she said that if the drug were approved, she worried that “the much larger group of women without any medical reason for their sexual distress will inevitably be misinformed and misled into thinking that there is a pill that can get them the sex life they read about, the one they think everyone else is having.”

Boehringer has also sponsored medical education classes for doctors and nurses about hypoactive sexual desire disorder.

In one course, released online in May, a quiz asked doctors to diagnose the condition of a 42-year-old working mother who takes care of three children and her own sick mother, and who had no desire for sex. (Her husband is mentioned only in passing.)

The correct answer? Schedule a follow-up visit to evaluate whether she has diagnosable hypoactive sexual desire disorder.

Personal comment: I can attest to the libido enhancing effect of dopamine, which I take to reduce my milk output to prevent my breasts increasing - from all the nipple stimulation from being frequent milked - to more than a 32B cup. We have been using Boehringer Ingelheim’s Flibanserin in our escort training classes. We got it through Adolph’s German connections and have established a clinical trial protocol so it’s legal to use it for ‘desire enhancement’ with our escort trainees. We don’t use it to treat hypoactive sexual desire disorder (HSDD), all of our escort candidates have very healthy libidos, we use it to enhance their libidos further to offset anxiety about some of the more adventuresome sexual encounters they are involved in during training and it works wonderfully well for that.

Adolph is having Abigail (Abi) his new Pool-Assistant take it so she will show a bit more enthusiasm as a submissive (she's primarily Domme and isn’t really submissive in any real sense) for her encounters with him rather than trying to dominate him. He enjoyed the encounters with Elke where he was able to subdue and dominate her, but apparently Abi has an even stronger will (she is Prussian) and he needs an edge. Otherwise, he says, he is afraid he will kill her during a sexual encounter while trying to bend her to his will. It can take a few weeks for the drug to take effect – she has been on it for three weeks and there is another week to go before meaningful effects can be seen. Patience is not one of Adolph’s virtues and his temper when with her is getting worse by the day. Abi thinks its fun and is enjoying tormenting him.